You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Belgian Society of Medical Oncology has partnered with Illumina, OncoDNA, and PierianDx for this study, which will enroll 864 patients with advanced metastatic cancer.
The company has started a program to increase access to tumor molecular profiling and precision oncology treatments for minority, low-income, and LGBTQ patients.
Later this year, the inherited cardiovascular disease clinic also plans to implement a preventive genomics program with polygenic risk score and PGx testing.
The service will offer whole-genome sequencing to English patients with rare diseases and cancer as part of routine care.
Multinational nephrology firm Fresenius Medical Care eventually wants as many as 200,000 samples in its registry and aims to sequence 20,000 patients this year.
The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
The Helix Laboratory Platform is the first whole-exome sequencing platform to receive do novo authorization by the agency and paves the way for others.
The Gene Curation Coalition, led by the Broad Institute, is serving as a clearinghouse of sorts for curated datasets on Mendelian disorders.
Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.
The combined solution will give health systems access to real-time genetics expertise so they can integrate genetic test results into patients' care.
The researchers also examined the contribution of rare variants to inflammatory bowel disease to find a potential targetable pathway.
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
The method may improve the performance of circulating tumor DNA-based detection assays for routine screening and cancer relapse testing.
The program uses an informatics system that converts genotype results to "traffic lights" telling clinicians whether a drug is acceptable for a certain patient.
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
Aetna's move comes at a time when a number of insurers including UnitedHealthcare have begun offering coverage of NIPT for average-risk pregnancies.
Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center will join Illumina to sequence the genomes of thousands of patients.
The clinical next-generation sequencing instrument is Illumina's second to receive approval from China's National Medical Products Administration.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.